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Purpose: The purpose of this study was to compare the aqueous humor concentrations of 
bimatoprost acid after topical instillation in rabbits of bimatoprost ophthalmic solution 0.01% 
and bimatoprost ophthalmic solution 0.03%, two commercially available intraocular pressure-
lowering medications.
Methods: Male Dutch Belted rabbits were divided into two treatment groups (four rabbits/eight 
eyes per group): bimatoprost 0.01% and bimatoprost 0.03%. Thirty microliters (µL) of study 
medication was to pically instilled into both eyes of each animal. Thirty minutes and 90 min-
utes after instillation, aqueous humor samples were collected. These samples were analyzed by 
reverse-phase high-performance liquid chromatography for bimatoprost acid concentration.
Results: Following a single topical ocular instillation, the bimatoprost 0.01% formulation had 
a lower mean aqueous humor concentration of bimatoprost acid than the bimatoprost 0.03% 
formulation at both 30 minutes (11.5 ± 2.1 ng/mL versus 37.8 ± 28.8 ng/mL; P = 0.17) and 
90 minutes (20.8 ± 5.7 ng/mL versus 45.8 ± 14.3 ng/mL; P = 0.03) after topical instillation.
Conclusions: Topical ocular instillation of bimatoprost 0.01% produced significantly lower 
bimatoprost acid concentration in the aqueous humor of rabbits than bimatoprost 0.03%, despite 
the 4-fold increase of benzalkonium chloride contained in bimatoprost 0.01%.
Keywords: aqueous humor, benzalkonium chloride, bimatoprost, pharmacokinetics, preclini-
cal, prostaglandin analog
Introduction
Patients with glaucoma, the second leading cause of vision loss worldwide,1 are often 
treated with prostaglandin analogs to reduce elevated intraocular pressure (IOP). 
Bimatoprost 0.03% (Lumigan®, Allergan Inc, Irvine, CA) is one such prostaglandin 
analog that decreases IOP by promoting uveoscleral aqueous outflow via activation of 
the prostaglandin F receptor.2 Bimatoprost is a prodrug that is hydrolyzed by esterases to 
release its active moiety, bimatoprost acid, into the aqueous humor.2 Although bimato-
prost is efficacious in reducing elevated IOP in patients with open-angle glaucoma or 
ocular hypertension,3 it is associated with a number of side effects, the most frequent 
of which is conjunctival hyperemia, affecting up to 45% of patients and accounting 
for discontinuation of therapy in 3% of patients.4
A new formulation of bimatoprost containing a lower concentration of drug 
(Lumigan 0.01%, Allergan Inc) has been developed in an attempt to improve the safety 
profile of this product.5 Bimatoprost 0.01% also contains a 4-fold greater concentration 
of the commonly used ophthalmic preservative, benzalkonium chloride (BAK), than 
bimatoprost 0.03% (0.02% BAK versus 0.005% BAK). In addition to its function as a Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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preservative, in vitro evidence suggests that BAK may facili-
tate topical ocular drug delivery by increasing transcorneal 
drug penetration of some medications,6 which another study 
demonstrated can occur in a dose-dependent manner.7 The 
goal of the current study was to determine whether bimato-
prost ophthalmic solution 0.01% with 0.02% BAK improves 
ocular penetration relative to bimatoprost ophthalmic solution 
0.03% with 0.005% BAK by comparing the aqueous humor 
concentrations of bimatoprost acid, the active metabolite of 
bimatoprost, after topical instillation of both commercial 
formulations of bimatoprost in rabbits.
Methods
Animals
Eight healthy male Dutch Belted rabbits weighing approxi-
mately 2 kg were used. Animals were treated in accordance 
with the Association for Research in Vision and Ophthal-
mology statement for Use of Animals in Ophthalmic and 
Vision Research. The study was conducted at an independent 
contract laboratory (PharmOptima, Portage, MI).
study design
Rabbits (eight eyes per group) were treated with one of 
two commercially available bimatoprost formulations: 
  bimatoprost ophthalmic solution 0.01% (Lumigan 0.01%, 
Allergan Inc, Ontario, Canada) or bimatoprost ophthalmic 
solution 0.03% (Lumigan 0.03%, Allergan Inc, Irvine, CA). 
Thirty   microliters of the study medication was instilled in both 
eyes of each animal. For each group, 50 µL aqueous humor 
samples were collected from each eye using a 28-gauge, 
0.5-inch needle at 30 minutes or 90 minutes after study medica-
tion instillation, for a total of four samples per time point. Each 
sample was analyzed for bimatoprost acid concentration.
sample preparation
Each aqueous humor sample was mixed with 50 µL methanol 
and 100 µL acetonitrile containing reserpine (internal stan-
dard) solution at 2.0 µg/mL. All samples were vortexed for 
30 seconds, followed by centrifugation at 14,000 rpm and 
at 4°C for 10 minutes. The supernatants were decanted into 
autosampler vials and stored at −20°C until time of analysis 
by high-performance liquid chromatography (HPLC).
high-performance liquid chromatography
Aqueous humor concentrations of bimatoprost acid were 
determined by an independent laboratory using a validated 
HPLC method. Chromatography was performed on a   Hypersil 
Gold, 50 × 2.1 mm, 5 µm with precolumn filter (Thermo 
  Scientific, Rockford, IL). The mobile phase consisted of firstly 
0.1% formic acid in water and secondly 0.1% formic acid in 
methanol. Analysis of 10 µL samples was performed on a 
TSQ Quantum Access (Thermo Scientific). The lower limit 
of quantitation for bimatoprost acid was 1.00 ng/mL.
Results
As shown in Figure 1, the mean aqueous humor concentra-
tion of bimatoprost acid was lower in the bimatoprost 0.01% 
group than in the bimatoprost 0.03% group after 30 minutes 
(11.5 ± 2.1 ng/mL versus 37.8 ± 28.8 ng/mL; P = 0.17) and 
90 minutes (20.8 ± 5.7 ng/mL versus 45.8 ± 14.3 ng/mL; 
P = 0.03) following topical administration. The mean aque-
ous humor concentration of bimatoprost acid at 30 minutes 
and 90 minutes postdose was approximately 3.3-fold and 
2.2-fold lower, respectively, in the bimatoprost 0.01% group 
than in the bimatoprost 0.03% group.
Discussion
Although the original formulation of bimatoprost ophthalmic 
solution has a favorable IOP-lowering efficacy,8–10 it produces 
conjunctival hyperemia in nearly half of patients.4 The newer 
formulation of bimatoprost was designed to improve upon 
the tolerability of topical bimatoprost by lowering the drug 
concentration from 0.03% to 0.01%. The amount of BAK was 
increased 4-fold (from 0.005% BAK to 0.02% BAK) in the 
revised bimatoprost 0.01% formulation, in an attempt to com-
pensate for the 67% reduction in bimatoprost concentration 
and the expected loss of ocular bioavailability of the revised 
formulation.5 BAK has been shown to improve corneal 
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Figure 1 Mean aqueous humor concentrations (n = 4 each) of bimatoprost acid 
after instillation of bimatoprost 0.01% or bimatoprost 0.03%.
Notes: *P = 0.03 bimatoprost acid 0.01% vs bimatoprost acid 0.03%. student’s 
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penetration in some animal models,6,11 possibly through 
the loss of tight junctions in the corneal epithelium.11,12 
However, in the current in vivo rabbit pharmacokinetic 
study of these two commercially available bimatoprost 
products, the newer 0.01% formulation demonstrated a 
lower mean aqueous humor concentration of bimatoprost 
acid than the original 0.03% formulation after a single 
topical ocular dose; this reduction in concentration was 
approaching statistical significance at 30 minutes and was 
statistically significant at 90 minutes post-dose. The results 
of this pharmacokinetic study show that, despite the 4-fold 
increase in BAK concentration in the revised bimatoprost 
0.01% formulation, it has significantly less ocular bioavail-
ability than the bimatoprost 0.03% formulation. Thus, the 
bimatoprost 0.01% group did not demonstrate improved 
corneal penetration when compared with the bimatoprost 
0.03% group, up to 90 minutes after topical ocular admin-
istration, despite the increased BAK concentration in the 
bimatoprost 0.01% formulation.
The decreased aqueous humor concentration of bimato-
prost acid observed with the lower concentration may 
translate into less drug reaching the target site of action, 
which could compromise the IOP-lowering effect of the 
revised bimatoprost 0.01% formulation. The only clinical 
study published that compares these two formulations 
showed that the bimatoprost 0.03% group had a numeri-
cally greater mean decrease in IOP (from baseline) than 
the bimatoprost 0.01% group at nearly every time point 
reported over the 12 months of the study, but these differ-
ences were within the 1.5 mmHg limit that designated a 
clinically relevant difference.5
The revised bimatoprost formulation may have an 
increased risk of ocular toxicity, particularly to the ocular 
surface. Numerous preclinical studies have established not 
only that BAK causes both corneal and conjunctival toxic-
ity, but also that this BAK toxicity is dose-dependent.13–16 
  Furthermore, clinical studies of glaucoma patients have 
reported increased ocular toxicity with IOP-lowering medi-
cations containing BAK.17,18
Because aqueous humor concentrations in the current 
study were measured only to 90 minutes postdose, no 
conclusions can be drawn regarding penetration that might 
have occurred after this time. However, within the para-
meters of the study design, the current study demonstrated 
that the increased BAK concentration in bimatoprost 0.01% 
did not adequately compensate for its 67% decrease in 
drug concentration, resulting in lower aqueous humor drug 
  concentrations than bimatoprost 0.03%. Due to the potential 
differences between rabbits and humans with respect to both 
corneal penetration of bimatoprost and response to BAK, the 
corneal penetration of the two commercial formulations of 
bimatoprost investigated in this study should be evaluated in 
a clinical trial. Furthermore, the long-term efficacy and safety 
of this new bimatoprost formulation can only be determined 
in a randomized clinical trial of adequate duration.
Disclosure
Medical writing assistance for this paper, provided by Jen-
nifer Klem, PhD, was funded by Alcon Laboratories, Inc.
References
  1.  Resnikoff S, Pascolini D, Etya’ale D, et al. Global data on 
visual impairment in the year 2002. Bull World Health Organ. 
2004;82(11):844–851.
  2.  Sharif NA, Williams GW, Kelly CR. Bimatoprost and its free 
acid are prostaglandin FP receptor agonists. Eur J Pharmacol. 
2001;432(2–3):211–213.
  3.  Patil AJ, Vajaranant TS, Edward DP. Bimatoprost – a review. Expert 
Opin Pharmacother. 2009;10(16):2759–2768.
  4.  Lumigan® [Package insert]. Irvine, CA: Allergan, Inc; 2006.
  5.  Katz LJ, Cohen JS, Batoosingh AL, Felix C, Shu V, Schiffman RM. 
Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 
0.0125%, and 0.03% in patients with glaucoma or ocular hypertension. 
Am J Ophthalmol. 2010;149(4):661–671.e1.
  6.  Majumdar S, Hippalgaonkar K, Repka MA. Effect of chitosan, 
benzalkonium chloride and ethylenediaminetetraacetic acid on 
permeation of acyclovir across isolated rabbit cornea. Int J Pharm. 
2008;348(1–2):175–178.
  7.  Keller N, Moore D, Carper D, Longwell A. Increased corneal permeability 
induced by the dual effects of transient tear film acidification and expo-
sure to benzalkonium chloride. Exp Eye Res. 1980;30(2):203–210.
  8.  How AC, Kumar RS, Chen YM, et al. A randomised crossover study 
comparing bimatoprost and latanoprost in subjects with primary angle 
closure glaucoma. Br J Ophthalmol. 2009;93(6):782–786.
  9.  Williams RD, Cohen JS, Gross RL, Liu CC, Safyan E, Batoosingh AL; 
for Bimatoprost Study Group. Long-term efficacy and safety of 
bimatoprost for intraocular pressure lowering in glaucoma and ocular 
hypertension: Year 4. Br J Ophthalmol. 2008;92(10):1387–1392.
  10.  Cantor LB, Hoop J, Morgan L, Wudunn D, Catoira Y; for Bimatoprost-
Travoprost Study Group. Intraocular pressure-lowering efficacy of 
bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma 
or ocular hypertension. Br J Ophthalmol. 2006;90(11):1370–1373.
  11.  Nakamura T, Yamada M, Teshima M, et al. Electrophysiological char-
acterization of tight junctional pathway of rabbit cornea treated with 
ophthalmic ingredients. Biol Pharm Bull. 2007;30(12):2360–2364.
  12.  McCarey B, Edelhauser H. In vivo corneal epithelial permeability 
  following treatment with prostaglandin analogs with or without 
  benzalkonium chloride. J Ocul Pharmacol Ther. 2007;23(5):445–451.
  13.  Epstein SP, Ahdoot M, Marcus E, Asbell PA. Comparative toxicity of 
preservatives on immortalized corneal and conjunctival epithelial cells. 
J Ocul Pharmacol Ther. 2009;25(2):113–119.
  14.  Epstein SP, Chen D, Asbell PA. Evaluation of biomarkers of inflamma-
tion in response to benzalkonium chloride on corneal and conjunctival 
epithelial cells. J Ocul Pharmacol Ther. 2009;25(5):415–424.
  15.  Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival 
changes caused by commonly used glaucoma medications. Cornea. 
2004;23(5):490–496.Clinical Ophthalmology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-ophthalmology-journal
Clinical Ophthalmology is an international, peer-reviewed journal 
covering all subspecialties within ophthalmology. Key topics include: 
Optometry; Visual science; Pharmacology and drug therapy in eye 
diseases; Basic Sciences; Primary and Secondary eye care; Patient 
Safety and Quality of Care Improvements. This journal is indexed on 
PubMed Central and CAS, and is the official journal of The Society of 
Clinical Ophthalmology (SCO). The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1450
Ogundele and Jasek
  16.  Lazarus HM, Imperia PS, Botti RE, Mack RJ, Lass JH. An in 
vitro method which assesses corneal epithelial toxicity due to 
  antineoplastic, preservative and antimicrobial agents. Lens Eye Toxic 
Res. 1989;6(1–2):59–85.
  17.  Horsley MB, Kahook MY. Effects of prostaglandin analog therapy 
on the ocular surface of glaucoma patients. Clin Ophthalmol. 
2009;3:291–295.
  18.  Uusitalo H, Chen E, Pfeiffer N, et al. Switching from a preserved 
to a preservative-free prostaglandin preparation in topical glaucoma 
  medication. Acta Ophthalmol. 2010;88(3):329–336.